Pharma BD Deal Intelligence
Ipsen's $797M all-cash acquisition of Memo Therapeutics buys potravitug, a Phase 2 first-in-class antibody for BK polyomavirus-associated nephropathy in kidney-transplant patients—a serious complication with no approved therapy. The EUR200M upfront, EUR500M milestone structure signals confidence, though a Phase 2-only asset carries real clinical risk before the Q3 2026 close.
First-in-class BK polyomavirus antibody deepening Ipsen's rare-disease franchise
Full analysis, sources & comparables →Ipsen agreed to acquire Swiss biotech Memo Therapeutics AG under a definitive share purchase agreement, adding potravitug, a Phase 2 first-in-class monoclonal antibody against BK polyomavirus (BKPyV). Terms: EUR200 million upfront and up to EUR500 million in milestones (total potential consideration exceeding EUR700 million / ~$797M). Potravitug targets BK polyomavirus-associated nephropathy (BKPyVAN), a serious complication in kidney-transplant recipients with no approved therapy. The all-cash transaction is expected to close in Q3 2026.
BK polyomavirus-associated nephropathy (BKPyVAN) is a frequent and serious complication in kidney-transplant recipients that can cause graft loss and transplant failure; there is no approved therapy. Potravitug is a first-in-class Phase 2 monoclonal antibody targeting BK polyomavirus, aiming to control viral replication and preserve graft function.
Ipsen agrees to acquire Memo Therapeutics for EUR200M upfront + up to EUR500M milestones (>EUR700M total), adding Phase 2 anti-BKPyV antibody potravitug. All-cash; close expected Q3 2026.
First-in-class asset in a no-approved-therapy transplant indication fits Ipsen's rare-disease strategy; return hinges on Phase 2/3 progression.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Memo Therapeutics AG (this deal) | 2026 | $797M | 66 |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2026 deals · Ipsen S.A. deals · Nephrology deals